David A Rizzieri, MD
Duke University
6
6
2
N/A
0
6
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+2 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Mojca Jongen-Lavrencic, MD
Erasmus Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Raoul Tibes, MD
Mayo Clinic Scottsdale-Phoenix
Shared therapeutic areas:
Worked with same sponsors:
Jesus Berdeja, MD
SCRI Development Innovations, LLC
Shared therapeutic areas:
Worked with same sponsors:
Hartmut Döhner, MD
Universitätsklinikum Ulm
Shared therapeutic areas:
Worked with same sponsors:
Martin S. Tallman, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Jessica Altman, MD
Northwestern University
Shared therapeutic areas:
Worked with same sponsors:
Guillermo Garcia-Manero, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Yves Beguin, MD, PhD
CHU-ULg
Shared therapeutic areas:
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Sorafenib in Myelodysplastic Syndrome
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
All 6 trials loaded